On February 25, 2026, Novocure announced FDA approval of its Optune Pax system for patients with locally advanced pancreatic cancer, marking the first regulatory green light for a new treatment in this indication in three decades. The approval follows pivotal trials demonstrating safety and efficacy of tumor-treating fields delivered via a wearable device.

Pancreatic cancer remains one of the deadliest malignancies with few effective second-line therapies; the locally advanced segment represents a multi-hundred-million-dollar market opportunity. Novocure plans a phased commercial rollout in the U.S. later this year, leveraging its existing field-delivery infrastructure and collaborating with oncology centers to train staff on device usage.

This approval broadens Novocure’s clinical footprint beyond its established glioblastoma indication for Optune, diversifying revenue streams and strengthening the company’s position in oncology. The new indication is expected to drive incremental device sales and support research into additional tumor-treating field applications.